Abstract:Objective\r\nTo investigate the clinical and laboratory characteristics of patients with Ph chromosome/BCR-ABL gene-positive acute myeloid leukemia (Ph/BCR-ABL+ AML).\r\n\r\n\r\nMethods\r\nThe clinical date of 15 primary patients with Ph/BCR-ABL+ AML were collected to retrospectively analyze the cell morphology, cytogenetics and cellular immunophenotyping, clinical features and prognosis.\r\n\r\n\r\nResults\r\nThe detection rate of Ph+ AML patients among AML in the same period was 1.47% (15/1 018). The results showed that 15 patients (8 males and 7 females) were diagnosed as Ph/BCR-ABL+ AML, whose median age was 38 years old and median white blood cell count was 38×109/L; 6 cases (40%) were extramedullary infiltration; according to French-American-Britain classification style, there were 8 cases of M2 (53.3%) and 4 cases of M4 (26.7%). Immnologic analysis showed that 15 Ph+ AML patients expressed myeloid antigens and CD34, of which 3 cases were immunophenotyped with myeloid and lymphoid cell antigens. In the initial diagnosis Ph positive chromosome can be detected in the 15 patients, and some chromosomes were associated with additional chromosomal abnormalities in 3 cases. BCR-ABL fusion gene transcript positive were detected in all cases, with P190BCR-ABL in 4 cases (26.7%), P210BCR-ABL in 11 cases (73.3%), among which 1 case coexpressed CBFβ-MYH11. Four out of 8 cases had AML-like gene mutations. Nine of 15 patients were completely relieved after one course of induction therapy. The complete remission (CR) rate (85.7%) in chemotherapy combined with tyrosine kinase inhibitor (TKI) group was better than that in signle chemotherapy group (37.5%), but the difference was not statistically significant (P=0.12). Median survival time of chemotherapy combined with TKI group (13 months) and chemotherapy combined with hematopoietic stem cell transplantation (HSCT) group (60 months) were both better than that of single chemotherapy group (8 months), P=0.0064, 0.0400. At the end of the follow-up, all patients in chemotherapy combined with TKI group and HSCT groups survived.\r\n\r\n\r\nConclusions\r\nThere are special characteristics in the clinical symptoms, cellular immune phenotypes and morphology of Ph/BCR-ABL+ AML. Routine screening of BCR-ABL fusion gene, AML common mutant gene and the chromosome provides more evidence for early diagnosis of leukemia. Efficacy on Ph/BCR-ABL+ AML is poor and survival time is short, but implement allogeneic hematopoietic stem cell transplantation after chemotherapy combined with TKI could improve prognosis.\r\n\r\n\r\nKey words: \r\nPh chromosome; Acute myeloid leukemia; BCR-ABL fusion gene

Detection of Philadelphia Chromosome and BCR-ABL Fusion Gene in Patients with Chronic Myeloid Leukemia by Cytogenetic Analysis and RT-PCR Technique

[Cytogenetic and Molecular Analysis of 1193 Cases with Chronic Myeloid Leukemia].

[Cytogenetic Analysis on 135 Cases of Chronic Myelogenous Leukemias with Non-Simple Philadelphia Chromosome].

Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Cytogenetic Analysis of 1863 Chineses Patients with Chronic Myeloid Leukemia

Analysis of Two Mutations in the BCR-ABL Fusion Gene Relevant for Monitoring Chronic Myeloid Leukemia Patients

Advantages of Digital PCR in the Detection of Low Abundance BCR-ABL1 Gene in Patients with Chronic Myeloid Leukemia

Cytogenetic Analysis of 55 Cases of Philadelphia Chromosome (ph+) Leukemia

Genetic characteristics of Philadelphia chromosome in patients with chronic myelogenous leukemia

Cytogenetic analysis of 362 cases of chronic myeloid leukemia]

Detection of BCR-ABL Fusion Gene by Multiplex RT-PCR Combining with Capillary Electrophoresis

Evaluation of a new flow cytometry based method for detection of BCR-ABL1 fusion protein in chronic myeloid leukemia

Molecular Detection of BCR-ABL in Chronic Myeloid Leukemia.

Quantitative detection of BCR–ABL fusion gene and its application in monitoring chronic myeloid leukemia treatment

Clinical and laboratorial characteristics analysis on 15 cases of acute myeloid leukemia with Ph chromosome and BCR-ABL gene positive

[Detection and quantification of BCR-ABL transcripts in patients with chronic myeloid leukemia by real-time quantitative reverse transcriptase polymerase chain reaction].

Application of real-time quantification polymerase chain reaction in detecting the expression of BCR-ABL in chronic myelogenous leukemia cells

Flow Cytometric Measurement of Blood Cells with BCR-ABL1 Fusion Protein in Chronic Myeloid Leukemia

Study on the cases with BCR/ABL fusion gene positively detected by fluorescence in situ hybridization

Laboratory Monitoring of Chronic Myeloid Leukemia in Patients on Tyrosine Kinase Inhibitors